1. ALLA AKTIER
  2. NYHETER
  3. IRLAB THERAPEUTICS

IRLAB Therapeutics

Nyheter IRLAB Therapeutics Nyheter alla bolag
Hej Visste du att du med vår premiumtjänst får fullständig historik i alla grafer, pressmeddelanden och andra notiser för dina favoritbolag direkt som DM i Discord samt en del andra godsaker? Du slipper dessutom störande annonser på sajten. Testa gratis i 14 dagar!

IRLAB publishes the Annual Report for 2025

REG

Gothenburg, Sweden, April 29, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, announced today that the Annual Report for 2025 is published on the company’s website, www.irlab.se.

IRLAB has published the Annual Report 2025 for the financial year, which covers January 1 to December 31, 2025. The Annual Report is available, in Swedish, on IRLAB’s website: Financial reports – IRLAB.  (The Annual Report is only published in Swedish)

For more information

Kristina Torfgård, CEO
Phone: +46 730 60 70 99
E-mail: kristina.torfgard@irlab.se

Gustaf Albèrt, CFO
Phone: +46 709 168 302
E-mail: gustaf.albert@irlab.se

This information is information that IRLAB Therapeutics is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-04-29 16:30 CEST.

About IRLAB

IRLAB discovers and develops a portfolio of transformative treatments for all stages of Parkinson's disease. The company originates from Nobel Laureate Prof Arvid Carlsson's research group and the discovery of a link between brain neurotransmitter disorders and brain diseases. Mesdopetam (IRL790), under development for treating levodopa-induced dyskinesias, has completed Phase IIb and is in preparation for Phase III. Pirepemat (IRL752), currently in Phase IIb, is being evaluated for its effect on fall frequency in Parkinson's disease. IRL757, a compound being developed for the treatment of apathy in neurodegenerative disorders, is in Phase Ib. In addition, the company is developing two preclinical programs, IRL942 and IRL1117, towards Phase I studies. IRLAB's pipeline has been generated by the company's proprietary systems biology-based research platform Integrative Screening Process (ISP). Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit www.irlab.se.

Attachments

IRLAB ÅR 2025 Final
549300JAT34LHEI0DH60-2025-12-31-1-sv (2)

Datum 2026-04-29, kl 16:30
Källa MFN
Bifogade filer
IRLAB ÅR 2025 Final
549300JAT34LHEI0DH60-2025-12-31-1-sv (2)